Mene Pangalos | Executive Vice President, IMED Biotech Unit & Global Business Development

Mene Pangalos, Executive Vice President, IMED Biotech Unit & Global Business Development, AstraZeneca

Mene Pangalos, Ph.D. is Executive Vice President of AstraZeneca’s Innovative Medicines and Early Development Biotech Unit and Global Business Development.  A member of the company’s Senior Executive team, Mene has overall responsibility for the company’s discovery research and early development activities across small molecules, oligonucleotides and other emerging drug platforms. 
Since joining AstraZeneca in 2010, Mene has been instrumental in transforming the company’s commitment to science.  He has led the transformation of R&D productivity through the development and implementation of the “5R” framework (recently published in Nature Reviews Drug Discovery); driven greater collaboration with academic, NGO and peer organisations; pioneered programmes to promote more open innovation and fostered a science driven culture that rewards truth-seeking behaviours.
As one of AstraZeneca’s leading scientists, Mene has published more than 140 peer-reviewed articles in scientific journals and has served as an editor of books and journals in neuroscience. 
Mene is also a leading figure in UK science, and is a Fellow of the Academy of Medical Sciences and of the Royal Society of Biology.  He is a Visiting Professor of Neuroscience at King’s College London, is a Fellow of Clare Hall at the University of Cambridge and recently awarded honorary degree of Doctor of Science from the University of Glasgow.  Mene serves on the Medical Research Council (MRC), the council for the National Centre for Universities and Business, the Prime Minister’s Research Champion Group for Dementia, and is part of the Ministerial Industry Strategy Group, and is a Non-Executive Director of the UK Precision Medicine Catapult.
Mene is also overseeing the creation of AstraZeneca’s new £500 million research centre in Cambridge - a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.


BioData EU- Day 2 @ 09:00

Transforming R&D productivity: How can we better turn science into medicine?

  • The future treatment for many of today’s diseases lies in discovering new biology to develop novel therapies. The advent of the genomics revolution brings with it an expanding list of pathways and targets to pursue – and with it, new drug discovery challenges
  • Validating drug targets by understanding and challenging scientific hypotheses has never been more important
  • Combining new technologies, focusing on medical understanding, challenging scientific hypotheses and driving strategic partnerships, we are making real progress in our ability to define and prosecute innovative treatment approaches for a variety of complex diseases

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Alistair Wilmot
+44 (0)207 092 1174

To speak:
Chris Shanks
+44 (0)207 092 1151